CANNABICS PHARMACEUTICALS INC.
(Note: This is NOT an IPO. This is an uplisting to the NASDAQ from the OTCQB. IPOScoop has NO CALL on uplistings.)
(From the prospectus: “Our common stock trades on the OTCQB under the symbol “CNBX” and the last sale on Feb. 17, 2022, was $0.08 per share. We expect to effect a reverse split of our common stock at a ratio within a range to be determined by our shareholders at a ratio and date to be determined by our Board of Directors prior to the listing of our common stock on the Nasdaq Capital Market. The share and per share information in this prospectus do not reflect such reverse stock split.”)
We are a pre-clinical-stage platform technology biopharmaceutical company, which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer (“CRC”). Our drug candidate under development for CRC is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or “window of opportunity” at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy.
The RCC-33 proprietary formula consists of a specific synthetic cannabinoid molecular composition that has demonstrated the potential to reduce CRC tumor volume by over 30% in repeated in-vivo studies performed.
We intend to initiate Phase I/II clinical trials in 2023. Neoadjuvant treatment is the administration of antitumor therapy as a first step to shrink a cancerous tumor prior to surgical intervention, and our business strategy is to advance our programs through clinical studies including with partners, and to opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development. Our activities are centered around our biological laboratory facilities located in Rehovot, Israel, where our scientific team leads our research and development efforts.
CRC (colorectal cancer) is the 3rd most diagnosed and 2nd most lethal of all cancers, with approximately 2 million new cases being diagnosed annually worldwide and a current market estimated at $9.26 billion, and which is expected to reach $16.6 billion by 2026.
|Address||# 3 Bethesda Metro Center, Suite 700 Bethesda, MD 20814|
|Phone Number||(877) 424-2429|
|View Prospectus:||CANNABICS PHARMACEUTICALS INC.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-3.19 mil (last 12 months)|
|Price range||$0.00 - $0.00|
|Est. $ Volume||$0.0 mil|
|Manager / Joint Managers||Roth Capital Partners|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|